Therapeutic Action
Antiretroviral, HIV protease inhibitor
PDF page 285
Loading InternPractice…
Drug reference
Antiretroviral, HIV protease inhibitor
PDF page 285
Booster for protease inhibitors (atazanavir, darunavir, lopinavir, etc.) in HIV infection. Ritonavir should not be used alone.
PDF page 285
Do not administer to patients with severe hepatic impairment. Administer with caution and monitor use in patients with haemophilia (increased bleeding) or mild to moderate hepatic impairment. The adverse effects of ritonavir as a booster are also dependent on the boosted protease inhibitor. May cause: gastrointestinal disturbances, fatigue, headache, dizziness, paraesthesia, joint and muscle pain, taste disturbances, hyperglycaemia, hyperlipidaemia, lipodystrophy, conduction disorders; pancreatitis, hepatic disorders, skin rash sometimes severe; in this event, stop treatment immediately. Ritonavir reduces the efficacy of implants and oral contraceptives.: use injectable medroxyprogesterone or an intrauterine device. Only when combined with atazanavir, an oral contraceptive containing at least 30 micrograms of ethinylestradiol per tablet may also be used. Pregnancy: no contra-indication
PDF pages 285, 286
25 mg and 100 mg tablets
PDF page 285
Dosage depends on the administration schedule of the boosted protease inhibitor. The daily dose is administered once daily or in 2 divided doses. Child 14 to < 25 kg: 50 mg (two 25 mg tablets) 2 times daily, or 100 mg (four 25 mg tablets or one 100 mg tablet) once daily Child ≥ 25 kg and adult: 100 mg (one 100 mg tablet) once or 2 times daily
PDF page 285
Depending on the efficacy and tolerance of the boosted protease inhibitor and ritonavir.
PDF page 285
Take with meals. Tablets are not recommended in children < 14 kg. Also comes in fixed-dose combinations with other protease inhibitors (atazanavir, darunavir, lopinavir, etc.). Preferably use these formulations when available.
PDF page 286
– – Below 25 °C
PDF page 286
100 mg (one 100 mg tablet) once or 2 times daily
PDF page 285